{"success":true,"data":{"pressRelease":{"id":"123399","rtpr_id":"nBw2h1CcNa","ticker":"AMLX","exchange":"NASDAQ","all_tickers":["AMLX"],"title":"Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock","author":"Business Wire","published_at":"2026-08-20T03:06:00.064Z","article_body":"Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million\nUnderwritten Public Offering of Common Stock\n\nAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the\n“Company”) today announced the pricing of an upsized underwritten public\noffering of 14,090,000 shares of its common stock at a public offering price\nof $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day\noption to purchase up to an additional 2,113,500 shares of its common stock at\nthe public offering price per share, less underwriting discounts and\ncommissions. All of the shares of common stock are being offered by Amylyx.\nThe gross proceeds to Amylyx from this offering are expected to be $500.2\nmillion, before deducting underwriting discounts and commissions and offering\nexpenses and excluding any exercise of the underwriters’ option to purchase\nadditional shares.\n\nAmylyx intends to use the net proceeds from this offering, together with\nexisting cash, cash equivalents and marketable securities, for:\n\n\n * Pre-commercial activities for avexitide, including securing additional\nmanufacturing capacity;\n\n * Research and development; and\n\n * Working capital and other general corporate purposes.\n\nThe offering is expected to close on or about August 21, 2026, subject to the\nsatisfaction of customary closing conditions.\n\nLeerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital\nare acting as joint bookrunning managers for the offering.\n\nThe shares described above are being offered pursuant to a shelf registration\nstatement on Form S-3ASR (File No. 333-293956) that became automatically\neffective upon filing with the Securities and Exchange Commission (the\n“SEC”) on March 3, 2026. This offering is being made only by means of a\nprospectus supplement and an accompanying prospectus that form a part of the\nregistration statement.\n\nA preliminary prospectus supplement and accompanying prospectus relating to\nthe offering were filed with the SEC on August 18, 2026, and are available on\nthe SEC’s website located at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54592178&newsitemid=20260819148986&lan=en-US&anchor=www.sec.gov&index=1&md5=94c0faa4608969d3f70b746e9a299baa)\n. A final prospectus supplement containing additional information relating to\nthe offering and accompanying prospectus will be filed with the SEC and will\nbe available on the SEC’s website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54592178&newsitemid=20260819148986&lan=en-US&anchor=www.sec.gov&index=2&md5=6842c7507fc231e4fe97d6863a01987d)\n. When available, copies of the final prospectus supplement and the\naccompanying prospectus relating to this offering may also be obtained by\ncontacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th\nFloor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by\nemail at syndicate@leerink.com (mailto:syndicate@leerink.com) ; Morgan Stanley\n& Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,\nNew York, NY 10014, or by email at prospectus@morganstanley.com\n(mailto:prospectus@morganstanley.com) ; Guggenheim Securities, LLC, Attention:\nEquity Syndicate Department, 330 Madison Avenue, 8(th) Floor, New York, NY\n10017, telephone: (212) 518-9544, email:\nGSEquityProspectusDelivery@guggenheimsecurities.com\n(mailto:GSEquityProspectusDelivery@guggenheimsecurities.com) ; and LifeSci\nCapital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New\nYork, NY 10019, or by email at legalnotices@lifescicapital.com\n(mailto:legalnotices@lifescicapital.com) .\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy, nor shall there be any sale of these securities in any state\nor jurisdiction in which such offer, solicitation or sale would be unlawful\nprior to the registration or qualification under the securities laws of that\nstate or jurisdiction.\n\nAbout Amylyx Pharmaceuticals\n\nAmylyx’s mission is to usher in a new era of treating diseases with high\nunmet needs. Where others see challenges, Amylyx sees opportunities and\npursues them with urgency, rigorous science, and unwavering commitment to the\ncommunities it serves. Amylyx is currently focused on four investigational\ntherapies across several endocrine conditions and neurodegenerative diseases\nin which it believes it can make the greatest impact.\n\nForward-Looking Statements\n\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including\nwith respect to the completion of the offering, the potential exercise by the\nunderwriters of the option to purchase additional shares, the anticipated\nclosing date of the offering, the expected gross proceeds from the offering\nand the expected use of proceeds from the offering. No assurance can be given\nthat the offering will be completed. Because such statements are subject to\nrisks and uncertainties, actual results may differ materially from those\nexpressed or implied by such forward-looking statements. Any forward-looking\nstatements in this press release are based on management’s current\nexpectations of future events and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. Risks that contribute to the uncertain nature of the\nforward-looking statements include those risks and uncertainties set forth in\nAmylyx’s SEC filings, including Amylyx’s Annual Report on Form 10-K for\nthe year ended December 31, 2025, Quarterly Report on Form 10-Q for the\nquarterly period ended June 30, 2026 and its subsequent filings with the SEC.\nAll forward-looking statements contained in this press release speak only as\nof the date on which they were made. Amylyx undertakes no obligation to update\nsuch statements to reflect events that occur or circumstances that exist after\nthe date on which they were made except as required by law. In light of the\nforegoing, investors are urged not to rely on any forward-looking statement in\nreaching any conclusion or making any investment decision about any securities\nof Amylyx.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260819148986/en/\n(https://www.businesswire.com/news/home/20260819148986/en/)\n\nMedia \n\nAmylyx Media Team\n\n(857) 320-6191\n\namylyxmediateam@amylyx.com (mailto:amylyxmediateam@amylyx.com)\n\nInvestors \n\nLindsey Allen\n\n(857) 320-6244\n\nInvestors@amylyx.com (mailto:Investors@amylyx.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw2h1CcNa","title":"Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock","author":"Business Wire","ticker":"AMLX","created":"2026-08-20T03:06:00.064Z","tickers":["AMLX"],"exchange":"NASDAQ","article_body":"Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million\nUnderwritten Public Offering of Common Stock\n\nAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the\n“Company”) today announced the pricing of an upsized underwritten public\noffering of 14,090,000 shares of its common stock at a public offering price\nof $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day\noption to purchase up to an additional 2,113,500 shares of its common stock at\nthe public offering price per share, less underwriting discounts and\ncommissions. All of the shares of common stock are being offered by Amylyx.\nThe gross proceeds to Amylyx from this offering are expected to be $500.2\nmillion, before deducting underwriting discounts and commissions and offering\nexpenses and excluding any exercise of the underwriters’ option to purchase\nadditional shares.\n\nAmylyx intends to use the net proceeds from this offering, together with\nexisting cash, cash equivalents and marketable securities, for:\n\n\n * Pre-commercial activities for avexitide, including securing additional\nmanufacturing capacity;\n\n * Research and development; and\n\n * Working capital and other general corporate purposes.\n\nThe offering is expected to close on or about August 21, 2026, subject to the\nsatisfaction of customary closing conditions.\n\nLeerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital\nare acting as joint bookrunning managers for the offering.\n\nThe shares described above are being offered pursuant to a shelf registration\nstatement on Form S-3ASR (File No. 333-293956) that became automatically\neffective upon filing with the Securities and Exchange Commission (the\n“SEC”) on March 3, 2026. This offering is being made only by means of a\nprospectus supplement and an accompanying prospectus that form a part of the\nregistration statement.\n\nA preliminary prospectus supplement and accompanying prospectus relating to\nthe offering were filed with the SEC on August 18, 2026, and are available on\nthe SEC’s website located at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54592178&newsitemid=20260819148986&lan=en-US&anchor=www.sec.gov&index=1&md5=94c0faa4608969d3f70b746e9a299baa)\n. A final prospectus supplement containing additional information relating to\nthe offering and accompanying prospectus will be filed with the SEC and will\nbe available on the SEC’s website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54592178&newsitemid=20260819148986&lan=en-US&anchor=www.sec.gov&index=2&md5=6842c7507fc231e4fe97d6863a01987d)\n. When available, copies of the final prospectus supplement and the\naccompanying prospectus relating to this offering may also be obtained by\ncontacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th\nFloor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by\nemail at syndicate@leerink.com (mailto:syndicate@leerink.com) ; Morgan Stanley\n& Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,\nNew York, NY 10014, or by email at prospectus@morganstanley.com\n(mailto:prospectus@morganstanley.com) ; Guggenheim Securities, LLC, Attention:\nEquity Syndicate Department, 330 Madison Avenue, 8(th) Floor, New York, NY\n10017, telephone: (212) 518-9544, email:\nGSEquityProspectusDelivery@guggenheimsecurities.com\n(mailto:GSEquityProspectusDelivery@guggenheimsecurities.com) ; and LifeSci\nCapital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New\nYork, NY 10019, or by email at legalnotices@lifescicapital.com\n(mailto:legalnotices@lifescicapital.com) .\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy, nor shall there be any sale of these securities in any state\nor jurisdiction in which such offer, solicitation or sale would be unlawful\nprior to the registration or qualification under the securities laws of that\nstate or jurisdiction.\n\nAbout Amylyx Pharmaceuticals\n\nAmylyx’s mission is to usher in a new era of treating diseases with high\nunmet needs. Where others see challenges, Amylyx sees opportunities and\npursues them with urgency, rigorous science, and unwavering commitment to the\ncommunities it serves. Amylyx is currently focused on four investigational\ntherapies across several endocrine conditions and neurodegenerative diseases\nin which it believes it can make the greatest impact.\n\nForward-Looking Statements\n\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including\nwith respect to the completion of the offering, the potential exercise by the\nunderwriters of the option to purchase additional shares, the anticipated\nclosing date of the offering, the expected gross proceeds from the offering\nand the expected use of proceeds from the offering. No assurance can be given\nthat the offering will be completed. Because such statements are subject to\nrisks and uncertainties, actual results may differ materially from those\nexpressed or implied by such forward-looking statements. Any forward-looking\nstatements in this press release are based on management’s current\nexpectations of future events and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. Risks that contribute to the uncertain nature of the\nforward-looking statements include those risks and uncertainties set forth in\nAmylyx’s SEC filings, including Amylyx’s Annual Report on Form 10-K for\nthe year ended December 31, 2025, Quarterly Report on Form 10-Q for the\nquarterly period ended June 30, 2026 and its subsequent filings with the SEC.\nAll forward-looking statements contained in this press release speak only as\nof the date on which they were made. Amylyx undertakes no obligation to update\nsuch statements to reflect events that occur or circumstances that exist after\nthe date on which they were made except as required by law. In light of the\nforegoing, investors are urged not to rely on any forward-looking statement in\nreaching any conclusion or making any investment decision about any securities\nof Amylyx.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260819148986/en/\n(https://www.businesswire.com/news/home/20260819148986/en/)\n\nMedia \n\nAmylyx Media Team\n\n(857) 320-6191\n\namylyxmediateam@amylyx.com (mailto:amylyxmediateam@amylyx.com)\n\nInvestors \n\nLindsey Allen\n\n(857) 320-6244\n\nInvestors@amylyx.com (mailto:Investors@amylyx.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-20T03:06:00.136320285Z","server_sent_at_ms":1787195160136},"received_at":"2026-08-20T03:06:00.189Z","source_url":"https://www.businesswire.com/news/home/20260819148986/en/"},"analysis":{"id":"112378","press_release_id":"123399","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["use of proceeds includes 'working capital and other general corporate purposes'"],"eventType":"offering","narrative":"Amylyx Pharmaceuticals priced an upsized underwritten public offering of 14.09 million shares at $35.50 per share, targeting gross proceeds of approximately $500.2 million.\n\nUnderwriters were granted a 30-day option to purchase an additional 2.11 million shares at the public offering price.\n\nProceeds are allocated for pre-commercial activities for avexitide, research and development, and general corporate purposes.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Amylyx raises $500M in upsized offering to fund avexitide launch and pipeline."},"keyFigures":{"dealValueUsd":"$500.2 million","offeringPrice":"$35.50","sharesOffered":14090000,"customDimensions":{"underwriters_option_shares":2113500,"underwriters_option_duration_days":30}},"quotedText":"","namedEntities":{"people":[],"products":["avexitide"],"companies":[{"name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX"},{"name":"Leerink Partners","relationship":"underwriter"},{"name":"Morgan Stanley","relationship":"underwriter"},{"name":"Guggenheim Securities","relationship":"underwriter"},{"name":"LifeSci Capital","relationship":"underwriter"}],"dollarAmounts":[{"amount":"$500.2 million","context":"gross proceeds from offering"},{"amount":"$35.50","context":"public offering price per share"}]},"materialImpact":{"score":4,"reasoning":"The company is raising a substantial $500.2 million through the sale of 14.09 million primary shares, with an additional 2.11 million available via an over-allotment option. This represents significant dilution to existing shareholders."},"tickerRelevance":{"others":[],"primary":"AMLX"},"globalImportance":35,"audienceRelevance":45,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"mid_cap","eventGravity":"large_capital_raise","sectorWeight":"biotech"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"Amylyx Pharmaceuticals priced an upsized underwritten public offering of 14.09 million shares at $35.50 per share, targeting gross proceeds of approximately $500.2 million.\n\nUnderwriters were granted a 30-day option to purchase an additional 2.11 million shares at the public offering price.\n\nProceeds are allocated for pre-commercial activities for avexitide, research and development, and general corporate purposes.","key_figures":{"dealValueUsd":"$500.2 million","offeringPrice":"$35.50","sharesOffered":14090000,"customDimensions":{"underwriters_option_shares":2113500,"underwriters_option_duration_days":30}},"named_entities":{"people":[],"products":["avexitide"],"companies":[{"name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX"},{"name":"Leerink Partners","relationship":"underwriter"},{"name":"Morgan Stanley","relationship":"underwriter"},{"name":"Guggenheim Securities","relationship":"underwriter"},{"name":"LifeSci Capital","relationship":"underwriter"}],"dollarAmounts":[{"amount":"$500.2 million","context":"gross proceeds from offering"},{"amount":"$35.50","context":"public offering price per share"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-20T03:07:20.910Z","global_importance":35,"audience_relevance":45,"importance_components":{"tickerTier":"mid_cap","eventGravity":"large_capital_raise","sectorWeight":"biotech"}},"durationMs":80709,"modelName":"glm-4.7"}}